{"text": ["How", "An", "AbbVie", "Deal", "Sent", "This", "Biotech", "Stock", "To", "A", "2-Year", "High"], "created_at": "2018-02-21 21:32:42"}
{"text": ["ANTH", "Awaits", "RESULT", "In", "Mar.,", "HAIR", "Grows,", "NITE", "Shines,", "TRXC", "On", "Must-watch", "List"], "created_at": "2018-02-21 21:04:00"}
{"text": ["ANTH", "Awaits", "RESULT", "In", "Mar.,", "HAIR", "Grows,", "NITE", "Shines,", "TRXC", "On", "Must-watch", "List"], "created_at": "2018-02-21 21:04:00"}
{"text": ["Here\u2019s", "What", "The", "AbbVie", "and", "Voyager", "Therapeutics", "Deal", "Really", "Means"], "created_at": "2018-02-21 19:03:29"}
{"text": ["Can", "Johnson", "&", "Johnson", "Replace", "Remicade", "for", "$100", "Million", "Upfront?"], "created_at": "2018-02-21 14:09:04"}
{"text": ["Can", "Johnson", "&", "Johnson", "Replace", "Remicade", "for", "$100", "Million", "Upfront?"], "created_at": "2018-02-21 14:09:04"}
{"text": ["AbbVie,", "Neurocrine", "shares", "rise", "after", "positive", "results", "for", "uterine", "fibroids", "drug"], "created_at": "2018-02-21 13:34:19"}
{"text": ["AbbVie", "Announces", "Positive", "Topline", "Results", "from", "Phase", "3", "Study", "Evaluating", "Investigational", "Elagolix", "in", "Women", "with", "Uterine", "Fibroids"], "created_at": "2018-02-21 13:00:00"}
{"text": ["Canadians", "living", "with", "Moderate", "to", "Severe", "Hidradenitis", "Suppurativa", "are", "beginning", "to", "have", "public", "access", "to", "HUMIRA\u00ae", "(Adalimumab)", "to", "manage", "their", "disease"], "created_at": "2018-02-21 13:00:00"}
{"text": ["AbbVie", "Reports", "Positive", "Topline", "Results", "From", "Phase", "3", "Elagolix", "Study"], "created_at": "2018-02-21 08:13:00"}
{"text": ["AbbVie", "Reports", "Positive", "Topline", "Results", "From", "Phase", "3", "Elagolix", "Study"], "created_at": "2018-02-21 08:13:00"}
{"text": ["Trial", "Tests", "FTC\u2019s", "Power", "to", "Referee", "Drug", "Makers\u2019", "Fight", "Against", "Generics"], "created_at": "2018-02-21 04:33:28"}
